For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT00037180
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Colorectal Neoplasms
- Neoplasm Metastasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Celecoxib — DRUG
- Irinotecan — DRUG
- 5-fluorouracil — DRUG
- Leucovorin — DRUG
Study Details
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5FU), and leucovorin (also known as LV). Preclinical data from animal models suggest that the investigational drug may offer an effective means for preventing CPT-11/5FU/LV-induced diarrhea. It is also hypothesized that the investigational drug-mediated anti-angiogenesis could induce a favorable tumor response.
Key Dates
- Start date
- Apr 30, 2002
- Status verified
- Sep 2008
- Completion
- Jan 31, 2003
Study Design
- Enrollment
- 212 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36685 | - |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33308 | - |
| Pfizer Investigational Site | Port Saint Lucie | Florida | 34952 | - |
| Pfizer Investigational Site | Chicago | Illinois | 60631 | - |
| Pfizer Investigational Site | Saint Joseph | Missouri | 64507 | - |
| Pfizer Investigational Site | St Louis | Missouri | 63136 | - |
| Pfizer Investigational Site | Buffalo | New York | 14215 | - |
| Pfizer Investigational Site | Williamsville | New York | 14221 | - |
| Pfizer Investigational Site | Altoona | Pennsylvania | 16601 | - |
| Pfizer Investigational Site | Puyallup | Washington | 98372 | - |
| Pfizer Investigational Site | Yakima | Washington | 98902 | - |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53215 | - |
Find similar trials in Mobile, AL
Related Studies
- Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerPHASE3 · Recruiting · Surgimab · Duarte, California
- Changes in Reproductive and Sexual Health in People With Early Onset Colorectal CancerRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerPHASE3 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Glendale, Arizona
- Colonoscopy vs Stool Testing for Older Adults With Colon PolypsRecruiting · Dartmouth-Hitchcock Medical Center · Birmingham, Alabama